[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ivf-outcome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ivf-outcome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100583644","comparing-ivficsi-cycle-outcomes-of-post-ovulation-ovarian-stimulation-protocol-with-elonva-without-gnrh-antagonist-to-follicular-phase-day-2-stimulation-fixed-day-5-antagonist-protocol-100583644",false,"NCT06879002","Comparing IVF\u002FICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol","To Compare IVF\u002FICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Fixed Day 5 Antagonist Protocol","Inclusion Criteria:\n\n* Age 18 to 38 years old.\n* Normal Menstrual cycle of 25-35 days.\n* Body Weight 60to90 kg\n* AMH\\>1.3 - \\\u003C3 ng\u002Fm (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of \\>5 on menstrual cycle days 2-3,\n\nExclusion Criteria:\n\n* History of premature ovulation\n* Azoospermia\n* PCOS\n* Endometriosis AFS ¾\n* Endometrioma\n* Known chromosomal abnormalities",true,"FEMALE","18 Years","38 Years",{"count":21,"type":22},252,"ESTIMATED","8 Weeks","OBSERVATIONAL","There are several approaches to the timing of antagonist administration in IVF\u002FICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs \u002Fburden without having an impact on the outcome.",[27,28],"Stimulation in the Ovary","IVF Outcome",[30,31,32,33],"progesterone","premature ovulation","ovarian stimulation","luteal stimulation","NOT_YET_RECRUITING","2026-05-06",{"date":37,"type":38},"2026-05-07","ACTUAL",{"date":40,"type":22},"2026-12-30",{"date":42,"type":22},"2027-12-30",{"name":44,"class":45},"ART Fertility Clinics LLC","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100579955","the-roar-study-reactive-oxygen-species-and-reproduction-100579955","NCT06831019","The ROAR Study: Reactive Oxygen Species and Reproduction","ROAR","Inclusion Criteria:\n\n1. Female age 18-43 years\n2. Subjects planning blastocyst culture for preimplantation genetic screening (PGS) for aneuploidy.\n3. Male partners 18 years of age or older.\n4. Must be a registered patient at UCSF Center for Reproductive Health\n5. Patient and partner must both be physically present on the day of retreival\n\nExclusion Criteria:\n\n1. Female partner age 44 or older\n2. Planning fresh transfer (hybrid PGS cycle)\n3. Cleavage stage biopsy\n4. Planning to use frozen sperm","ALL","43 Years",{"count":57,"type":22},1100,"This is a prospective cohort study characterizing follicular fluid and serum levels of oxidative stress in women with various infertility diagnoses undergoing in vitro fertilization, and assessing the relationship of oxidative stress to oocyte competence as determined by embryo development outcomes. Furthermore, we will measure oxidative stress in sperm and correlate the overall oxidative stress within the couple with IVF and pregnancy outcomes of the resultant embryos.",[60,28,61],"Ovarian Aging","Oxidative Stress",[63,64],"oxidative stress","ovarian aging","RECRUITING","2026-02-12",{"date":68,"type":38},"2026-02-17",{"date":70,"type":38},"2025-07-07",{"date":72,"type":22},"2027-03-01",{"name":74,"class":45},"University of California, San Francisco",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":75},"100375027","trigger-timing-in-ovarian-stimulations-100375027","NCT04163133","Trigger Timing in Ovarian Stimulations","Comparison of Regular Trigger Timing and 1～2 Days Delay of Trigger in Ovarian Stimulations by GnRH Antagonist Protocol in in Vitro Fertilization","Inclusion Criteria:\n\n* Age: ≥18 and \\\u003C42 years old\n* AFC: ≥5 and \\\u003C20\n* AMH: ≥1.1 ng\u002FmL and \\\u003C2.5 ng\u002FmL\n* BMI: ≥18.5 Kg\u002Fm2 and \\\u003C29 Kg\u002Fm\n* First or second ART cycle\n* Regular menstrual cycles (between 22 and 35 days)\n* Two ovaries present\n* Planned for single or double day 3 transfer\n* Infertile couples scheduled for their first IVF\u002FICSI cycle with fixed antagonist protocol.\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Women with contraindication for IVF or ICSI, such as poorly controlled type 1 or type 2 diabetes mellitus; undiagnosed liver disease or dysfunction (based on serum liver enzyme test results); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus or cerebrovascular accident; uncontrolled hypertension or known symptomatic heart disease; history of (or suspected) cervical carcinoma, endometrial carcinoma or breast carcinoma; and undiagnosed vaginal bleeding.\n* Previous history of poor ovarian response (\\\u003C4 oocytes retrieved) with a maximal dose of OS (≥300 IU\u002Fday) or OHSS, regardless of gonadotropin dose\n* Known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis)\n* Repeated miscarriages (\\>2 previous biochemical pregnancies or \\>2 spontaneous miscarriages)\n* Recurrent implantation failure (\\>3 failed cycles with good quality embryos)\n* PCOS\n* Untreated thyroid disfunction\n* Administration of exogenous E2, P4 or gonadotropins in the preceding menstrual cycle\n* Active female smoking\n* Ongoing pregnancy\n* Women who have previously enrolled in the trial\n* Those unable to comprehend the investigational nature of the proposed study\n* either male partner or female partner has to receive donor sperm or donor eggs.\n* Either male partner or female partner has to receive PGD and PGS.","42 Years",{"count":85,"type":22},834,"INTERVENTIONAL",[88],"NA","The use of antagonist ovulation stimulation program is increasing year by year, because of its convenience, flexibility, and prevention effect of ovarian hyperstimulation syndrome. However, many researchers and clinicians believe that the clinical outcomes of antagonist regimens are worse than those of classical long-term regimens. Studies showed that the reasons for that maybe antagonist protocol results in poor effect on oocytes maturation or endometrial receptivity.\n\nAt present, the trigger time of antagonist regimen is more than three follicles with diameters of ≥17 mm, which makes the duration of gonadotrophin application in antagonist regimen is shorter than that of long regimen. Whether the trigger time of antagonist regimen is too early to cause adverse effects on oocytes, embryos and eventual clinical outcomes is unknown.\n\nThis study hopes to compare regular trigger timing and 1～2 days delay of trigger in ovarian stimulations by antagonist protocol，in order to study whether delay 1～2 days of trigger will get better clinical outcomes than regular trigger timing in ovarian stimulations by antagonist protocol in in vitro fertilization (IVF)\u002FIntracytoplasmic sperm injection (ICSI).\n\nThe results of this study will help infertile couples and clinicians to know and choose the optimal treatment in antagonist protocol.",[28],[92],"delay of trigger, ovarian stimulation, antagonist protocol","2025-12-30",{"date":95,"type":38},"2026-01-05",{"date":97,"type":38},"2020-04-01",{"date":99,"type":22},"2028-03-31",{"name":101,"class":45},"Peking University Third Hospital"]